Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Rectal Cancer | Research article

Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ|Rectalcarcinoma registry

Authors: Sven Lichthardt, Johanna Wagner, Stefan Löb, Niels Matthes, Caroline Kastner, Friedrich Anger, Christoph-Thomas Germer, Armin Wiegering

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Preoperative chemoradiotherapy is the recommended standard of care for patients with local advanced rectal cancer. However, it remains unclear, whether a prolonged time interval to surgery results in an increased perioperative morbidity, reduced TME quality or better pathological response. Aim of this study was to determine the time interval for best pathological response and perioperative outcome compared to current recommended interval of 6 to 8 weeks.

Methods

This is a retrospective analysis of the German StuDoQ|Rectalcarcinoma registry. Patients were grouped for the time intervals of “less than 6 weeks”, “6 to 8 weeks”, “8 to 10 weeks” and “more than 10 weeks”. Primary endpoint was pathological response, secondary endpoint TME quality and complications according to Clavien-Dindo classification.

Results

Due to our inclusion criteria (preoperative chemoradiation, surgery in curative intention, M0), 1.809 of 9.560 patients were suitable for analysis. We observed a trend for increased rates of pathological complete response (pCR: ypT0ypN0) and pathological good response (pGR: ypT0-1ypN0) for groups with a prolonged time interval which was not significant. Ultimately, it led to a steady state of pCR (16.5%) and pGR (22.6%) in “8 to 10” and “more than 10” weeks. We were not able to observe any differences between the subgroups in perioperative morbidity, proportion of rectal extirpation (for cancer of the lower third) or difference in TME quality.

Conclusion

A prolonged time interval between neoadjuvant chemoradiation can be performed, as the rate of pCR seems to be increased without influencing perioperative morbidity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.CrossRef Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.CrossRef
2.
go back to reference Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
3.
go back to reference Wiegering A, et al. Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades. BMC Cancer. 2014;14:816.CrossRef Wiegering A, et al. Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades. BMC Cancer. 2014;14:816.CrossRef
4.
go back to reference Camma C, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284(8):1008–15.CrossRef Camma C, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284(8):1008–15.CrossRef
5.
go back to reference Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.CrossRef Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.CrossRef
6.
go back to reference Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.CrossRef Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.CrossRef
8.
go back to reference Foster JD, et al. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum. 2013;56(7):921–30.CrossRef Foster JD, et al. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum. 2013;56(7):921–30.CrossRef
9.
go back to reference Petrelli F, et al. Increasing the interval between Neoadjuvant Chemoradiotherapy and surgery in rectal Cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.CrossRef Petrelli F, et al. Increasing the interval between Neoadjuvant Chemoradiotherapy and surgery in rectal Cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.CrossRef
10.
go back to reference Wang XJ, et al. Effect of interval between Neoadjuvant Chemoradiotherapy and surgery on oncological outcome for rectal Cancer: a systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:6756859.PubMedPubMedCentral Wang XJ, et al. Effect of interval between Neoadjuvant Chemoradiotherapy and surgery on oncological outcome for rectal Cancer: a systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:6756859.PubMedPubMedCentral
11.
go back to reference Habr-Gama A, São Julião GP, Fernandez LM, Vailati BB, Andrade A, Araújo SEA, Gama-Rodrigues J, Perez RO. Achieving a complete clinical response after Neoadjuvant Chemoradiation that does not require surgical resection: It may take longer than you think! Dis Colon Rectum. 2019. https://doi.org/10.1097/DCR.0000000000001338. [Epub ahead of print].CrossRef Habr-Gama A, São Julião GP, Fernandez LM, Vailati BB, Andrade A, Araújo SEA, Gama-Rodrigues J, Perez RO. Achieving a complete clinical response after Neoadjuvant Chemoradiation that does not require surgical resection: It may take longer than you think! Dis Colon Rectum. 2019. https://​doi.​org/​10.​1097/​DCR.​0000000000001338​. [Epub ahead of print].CrossRef
12.
go back to reference Garcia-Aguilar J, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66.CrossRef Garcia-Aguilar J, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66.CrossRef
13.
go back to reference Lefevre JH, et al. Effect of interval (7 or 11 weeks) between Neoadjuvant Radiochemotherapy and surgery on complete pathologic response in rectal Cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31):3773–80.CrossRef Lefevre JH, et al. Effect of interval (7 or 11 weeks) between Neoadjuvant Radiochemotherapy and surgery on complete pathologic response in rectal Cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31):3773–80.CrossRef
14.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRef
15.
go back to reference Wellner UF, et al. Laparoscopic versus open distal pancreatectomy-a propensity score-matched analysis from the German StuDoQ|pancreas registry. Int J Color Dis. 2017;32(2):273–80.CrossRef Wellner UF, et al. Laparoscopic versus open distal pancreatectomy-a propensity score-matched analysis from the German StuDoQ|pancreas registry. Int J Color Dis. 2017;32(2):273–80.CrossRef
16.
go back to reference Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.CrossRef Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.CrossRef
17.
go back to reference Herzog T, et al. TME quality in rectal cancer surgery. Eur J Med Res. 2010;15:292–6.CrossRef Herzog T, et al. TME quality in rectal cancer surgery. Eur J Med Res. 2010;15:292–6.CrossRef
18.
go back to reference Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin N Am. 2002;31(3):827–39.CrossRef Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin N Am. 2002;31(3):827–39.CrossRef
19.
go back to reference Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.CrossRef Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.CrossRef
20.
go back to reference Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–28.CrossRef Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–28.CrossRef
21.
go back to reference Zorcolo L, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19(9):2822–32.CrossRef Zorcolo L, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19(9):2822–32.CrossRef
22.
go back to reference de Campos-Lobato LF, et al. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg. 2011;15(3):444–50.CrossRef de Campos-Lobato LF, et al. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg. 2011;15(3):444–50.CrossRef
23.
go back to reference Probst CP, et al. Extended intervals after Neoadjuvant therapy in locally advanced rectal Cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430–40.CrossRef Probst CP, et al. Extended intervals after Neoadjuvant therapy in locally advanced rectal Cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430–40.CrossRef
24.
go back to reference Sloothaak DA, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933–9.CrossRef Sloothaak DA, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933–9.CrossRef
25.
go back to reference Wolthuis AM, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19(9):2833–41.CrossRef Wolthuis AM, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19(9):2833–41.CrossRef
26.
go back to reference Lefevre JH, et al. Does a longer waiting period after Neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal Cancer?: three Years' follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg. 2019;270(5):747–54.CrossRef Lefevre JH, et al. Does a longer waiting period after Neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal Cancer?: three Years' follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg. 2019;270(5):747–54.CrossRef
Metadata
Title
Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ|Rectalcarcinoma registry
Authors
Sven Lichthardt
Johanna Wagner
Stefan Löb
Niels Matthes
Caroline Kastner
Friedrich Anger
Christoph-Thomas Germer
Armin Wiegering
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-6538-8

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine